We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$98.4M
Cap. Flow %
-1.69%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
5.5 quarters
Top 10 Avg Time Held Equity only
6.1 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY icon
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC icon
BeOne Medicines Ltd
ONC
+$13M
4
BLUE icon
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.97%
4 Miscellaneous 13.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BUFF icon
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.48B 42.71%
87,460,875
– –
2015 Q3
8 quarters
WW icon
2
DELISTED
WW International
WW
$1.28B 22.09%
29,443,300
– –
2013 Q2
17 quarters
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$748M
$707M 12.18%
57,517,977
– –
2013 Q2
17 quarters
BAC icon
4
CALL
Bank of America
BAC
$380B
$250M 4.3%
9,850,000
+1,400,000
+17% +$34M
2016 Q1
6 quarters
GS icon
5
CALL
Goldman Sachs
GS
$261B
$47.4M 0.82%
200,000
-1,250,000
-86% -$282M
2017 Q1
2 quarters
INCY icon
6
Incyte
INCY
$22.9B
$46.7M 0.8%
400,000
– –
2014 Q1
14 quarters
BMY icon
7
CALL
Bristol-Myers Squibb
BMY
$121B
$41.4M 0.71%
650,000
-350,000
-35% -$20.4M
2016 Q3
4 quarters
AGN
8
CALL
DELISTED
Allergan plc
AGN
$41M 0.71%
+200,000
New +$46.5M
2017 Q3
0 quarters
WFC icon
9
CALL
Wells Fargo
WFC
$253B
$35.8M 0.62%
650,000
– –
2016 Q3
4 quarters
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.9B
$30M 0.52%
450,000
-250,000
-36% -$15M
2013 Q3
16 quarters
NKTR icon
11
Nektar Therapeutics
NKTR
$1.41B
$30M 0.52%
83,333
-10,000
-11% -$3.13M
2013 Q2
17 quarters
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.1B
$29.4M 0.51%
250,000
-25,000
-9% -$2.13M
2013 Q4
15 quarters
IBM icon
13
CALL
IBM
IBM
$214B
$29M 0.5%
209,200
– –
2016 Q2
5 quarters
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$26.1M 0.45%
700,000
– –
2016 Q2
5 quarters
NBIX icon
15
Neurocrine Biosciences
NBIX
$14.5B
$24.5M 0.42%
400,000
-150,000
-27% -$7.91M
2016 Q2
5 quarters
AAL icon
16
CALL
American Airlines Group
AAL
$8.45B
$23.7M 0.41%
+500,000
New +$24.2M
2017 Q3
0 quarters
ONC icon
17
BeOne Medicines Ltd
ONC
$40.1B
$23.3M 0.4%
225,000
-175,000
-44% -$13M
2016 Q4
3 quarters
BLK icon
18
CALL
Blackrock
BLK
$168B
$22.4M 0.39%
+50,000
New +$21.3M
2017 Q3
0 quarters
C icon
19
CALL
Citigroup
C
$217B
$21.8M 0.38%
300,000
-200,000
-40% -$13.7M
2017 Q1
2 quarters
MET icon
20
CALL
MetLife
MET
$62.5B
$20.8M 0.36%
400,000
-2,405,000
-86% -$117M
2014 Q1
14 quarters
GILD icon
21
CALL
Gilead Sciences
GILD
$187B
$20.3M 0.35%
250,000
-1,000,000
-80% -$76.5M
2017 Q1
2 quarters
INTC icon
22
CALL
Intel
INTC
$553B
$19M 0.33%
+500,000
New +$17.8M
2017 Q3
0 quarters
AMGN icon
23
CALL
Amgen
AMGN
$224B
$18.6M 0.32%
+100,000
New +$17.7M
2017 Q3
0 quarters
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$10.6B
$18.6M 0.32%
200,000
-50,000
-20% -$4.42M
2013 Q2
17 quarters
BLUE icon
25
DELISTED
bluebird bio
BLUE
$18.5M 0.32%
10,422
-8,878
-46% -$12.4M
2013 Q3
16 quarters
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group's Q3 2017 filing shows 20 new, 23 increased, 35 reduced and 17 closed positions. Its largest new stake was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M. The largest sale was Goldman Sachs, an estimated $22.6M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.